A CLINICAL STUDY CONDUCTED IN MULTIPLE CENTERS COMPARING VELIPARIB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL VERSUS A PLACEBO IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: